New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Pernot, Simon [3 ]
机构：
[1] Hop Rene Huguenin, Inst Curie, Dept Oncol Med, 35 Rue Dailly, F-92210 St Cloud, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] Inst Bergonie, Dept Oncol Med, 229 Cours Argonne, F-33000 Bordeaux, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 05期
关键词：
MULTICENTER;
D O I：
10.1016/j.bulcan.2021.03.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [1] Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
    Storandt, Michael H.
    Jin, Zhaohui
    Mahipal, Amit
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1265 - 1274
  • [2] Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia
    Yoshinori Kikuchi
    Kazuhisa Yamaguchi
    Ryo Shimizu
    Yuu Matsumoto
    Yasuko Kurose
    Naoki Okano
    Yuichirou Otsuka
    Kazutoshi Shibuya
    Takahisa Matsuda
    Hideaki Shimada
    International Cancer Conference Journal, 2023, 12 : 285 - 290
  • [3] Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia
    Kikuchi, Yoshinori
    Yamaguchi, Kazuhisa
    Shimizu, Ryo
    Matsumoto, Yuu
    Kurose, Yasuko
    Okano, Naoki
    Otsuka, Yuichirou
    Shibuya, Kazutoshi
    Matsuda, Takahisa
    Shimada, Hideaki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2023, 12 (04) : 285 - 290
  • [4] FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
    Patel, Timil H.
    Marcus, Leigh
    Horiba, M. Naomi
    Donoghue, Martha
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Schuck, Robert N.
    Li, Yangbing
    Zhang, Xinyuan
    Zirkelbach, Jeanne Fourie
    Charlab, Rosane
    Liu, Jiang
    Yang, Yuching
    Lemery, Steven J.
    Pazdur, Richard
    Theoret, Marc R.
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 838 - 842
  • [5] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
    Huang, X-W.
    Shi, G-M.
    Zhang, T.
    Bao, L-Q.
    Wen, T-F.
    Zhang, B.
    Peng, T.
    Zhao, H.
    Kuang, M.
    Wang, W-L.
    Ran, J-H.
    Liu, Y-B.
    Gong, W.
    Mou, H-B.
    Luo, Y.
    Wang, Y.
    Sun, H.
    Fan, J.
    Liu, L-X.
    Dai, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
  • [6] Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 gene rearrangement
    Byrne, Matthew M.
    Dunne, Richard F.
    Melaragno, Jennifer I.
    Chavez-Villa, Mariana
    Hezel, Aram
    Liao, Xiaoyan
    Ertreo, Marco
    Al-Judaibi, Bandar
    Orloff, Mark
    Hernandez-Alejandro, Roberto
    Tomiyama, Koji
    AMERICAN JOURNAL OF TRANSPLANTATION, 2025, 25 (03) : 623 - 627
  • [7] Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
    Ishido, Shun
    Tamaki, Nobuharu
    Inada, Kento
    Itakura, Jun
    Takahashi, Yuka
    Uchihara, Naoki
    Suzuki, Keito
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Matsumoto, Hiroaki
    Nobusawa, Tsubasa
    Keitoku, Taisei
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Kurosaki, Masayuki
    Izumi, Namiki
    CLINICAL CASE REPORTS, 2023, 11 (07):
  • [8] Pemazyre® (Pemigatinib) is available in Germany for the Treatment of Adults with locally advanced or metastatic Cholangiocarcinoma with Fusion or Rearrangement of the Fibroblast Growth Factor Receptor 2 (FGFR2)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 367 - 367
  • [9] Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review
    Washburn, Leslie
    Mahipal, Amit
    Jatoi, Aminah
    Kottschade, Lisa
    Tran, Nguyen
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2627 - 2636
  • [10] FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma
    Liu, Shaoqing
    Weng, Jialei
    Cao, Manqing
    Zhou, Qiang
    Xu, Min
    Xu, Wenxin
    Hu, Zhiqiu
    Xu, Minghao
    Dong, Qiongzhu
    Sheng, Xia
    Zhou, Chenhao
    Ren, Ning
    ONCOLOGIST, 2024, 29 (12): : e1734 - e1747
12345